HIV Sales Fuel Gilead’s Robust First Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech firm boasts record sales, record revenues.
You may also be interested in...
Gilead Boasts Vibrant Pipeline; Boosts R&D Spend Guidance
Biotech reports continuing increases in sales of its HIV combination drugs during second-quarter earnings call.
Gilead Boasts Vibrant Pipeline; Boosts R&D Spend Guidance
Biotech reports continuing increases in sales of its HIV combination drugs during second-quarter earnings call.
Gilead Gets Positive Recommendation From EU Committee To Market Viread For Hepatitis B
Company also awaits August PDUFA date for the same indication in the United States.